1. Home
  2. KNSA

as 09-05-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 1.9B IPO Year: 2018
Target Price: $40.83 AVG Volume (30 days): 439.9K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.07 EPS Growth: N/A
52 Week Low/High: $17.82 - $35.82 Next Earning Date: 10-28-2025
Revenue: $529,332,000 Revenue Growth: 56.18%
Revenue Growth (this year): 37.21% Revenue Growth (next year): 11.99%

KNSA Daily Stock ML Predictions

Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Tessari Eben KNSA CHIEF OPERATING OFFICER Sep 3 '25 Sell $35.50 15,091 $535,730.50 44,452
Megna Michael R KNSA CHIEF ACCOUNTING OFFICER Sep 3 '25 Sell $34.84 11,000 $383,240.00 38,011
Tessari Eben KNSA CHIEF OPERATING OFFICER Aug 18 '25 Sell $34.11 16,200 $547,141.00 44,452
Malley Thomas KNSA N/A Aug 14 '25 Sell $33.09 78,233 $2,588,729.97 12,546
Malley Thomas KNSA N/A Aug 13 '25 Sell $33.32 50,129 $1,670,298.28 12,546
Malley Thomas KNSA N/A Aug 12 '25 Sell $32.40 49,407 $1,600,786.80 12,546
Tessari Eben KNSA CHIEF OPERATING OFFICER Jun 16 '25 Sell $28.28 17,300 $489,244.00 44,452
Tessari Eben KNSA CHIEF OPERATING OFFICER Jun 9 '25 Sell $30.45 70,867 $2,160,035.40 44,452
Quart Barry D KNSA Director Jun 9 '25 Sell $30.34 27,448 $833,001.36 12,546

Share on Social Networks: